Published in Oncogene on July 01, 2004
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell (2008) 3.10
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73
Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol (2005) 1.65
LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol (2006) 1.55
Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol (2009) 1.52
c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem (2013) 1.37
Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39. Am J Hum Genet (2009) 1.21
Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer (2005) 1.16
Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology (2010) 1.05
Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res (2009) 1.05
FGF signaling regulates the number of posterior taste papillae by controlling progenitor field size. PLoS Genet (2011) 1.04
Regulation of sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol (2006) 1.03
Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis. Am J Respir Cell Mol Biol (2008) 1.00
Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene (2010) 0.99
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
The developing story of Sprouty and cancer. Cancer Metastasis Rev (2014) 0.96
Sprouty is a negative regulator of transforming growth factor β-induced epithelial-to-mesenchymal transition and cataract. Mol Med (2012) 0.95
Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res (2010) 0.94
A novel role of Sprouty 2 in regulating cellular apoptosis. J Biol Chem (2007) 0.92
HECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2. J Biol Chem (2009) 0.91
Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. J Biol Chem (2008) 0.87
Functional interaction between Env oncogene from Jaagsiekte sheep retrovirus and tumor suppressor Sprouty2. Retrovirology (2010) 0.86
Automated time-lapse microscopy and high-resolution tracking of cell migration. Cytotechnology (2006) 0.85
Cell migration regulates the kinetics of cytokinesis. Cell Cycle (2011) 0.83
Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. J Oncol (2012) 0.83
The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cells. J Ovarian Res (2014) 0.79
Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies. Curr Oncol (2007) 0.78
MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility. Oncotarget (2015) 0.78
Systematic analysis of copy number variants of a large cohort of orofacial cleft patients identifies candidate genes for orofacial clefts. Hum Genet (2015) 0.77
Fibrosis in the lens. Sprouty regulation of TGFβ-signaling prevents lens EMT leading to cataract. Exp Eye Res (2015) 0.76
Drug and bioactive molecule screening based on a bioelectrical impedance cell culture platform. Int J Nanomedicine (2014) 0.75
Sprouty2 mediated tuning of signalling is essential for somite myogenesis. BMC Med Genomics (2015) 0.75
Hypoxia inducible factors regulate the transcription of the sprouty2 gene and expression of the sprouty2 protein. PLoS One (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. J Cell Physiol (2005) 3.60
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Noninvasive assessment of collagen gel microstructure and mechanics using multiphoton microscopy. Biophys J (2006) 2.71
The effect of matrix density on the regulation of 3-D capillary morphogenesis. Biophys J (2007) 2.37
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
The use of poly(ethylene glycol) hydrogels to investigate the impact of ECM chemistry and mechanics on smooth muscle cells. Biomaterials (2006) 2.23
Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A (2007) 2.15
Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng Part A (2009) 2.14
HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem (2003) 2.08
Mesenchymal stem cells enhance angiogenesis in mechanically viable prevascularized tissues via early matrix metalloproteinase upregulation. Tissue Eng (2006) 1.98
MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell (2013) 1.95
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90
Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A (2006) 1.85
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Engineering microscale cellular niches for three-dimensional multicellular co-cultures. Lab Chip (2009) 1.77
The emergence of ECM mechanics and cytoskeletal tension as important regulators of cell function. Cell Biochem Biophys (2007) 1.62
HGF/SF-Met signaling in tumor progression. Cell Res (2005) 1.61
The decline in U.S. cancer mortality in people born since 1925. Cancer Res (2009) 1.61
Intrinsic mechanical properties of the extracellular matrix affect the behavior of pre-osteoblastic MC3T3-E1 cells. Am J Physiol Cell Physiol (2006) 1.60
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
The effects of matrix stiffness and RhoA on the phenotypic plasticity of smooth muscle cells in a 3-D biosynthetic hydrogel system. Biomaterials (2008) 1.51
Matrix composition regulates three-dimensional network formation by endothelial cells and mesenchymal stem cells in collagen/fibrin materials. Angiogenesis (2012) 1.47
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene (2002) 1.47
Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms. Exp Cell Res (2010) 1.43
ECM compliance regulates osteogenesis by influencing MAPK signaling downstream of RhoA and ROCK. J Bone Miner Res (2009) 1.43
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
Endothelial cell traction and ECM density influence both capillary morphogenesis and maintenance in 3-D. Am J Physiol Cell Physiol (2009) 1.42
Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol (2004) 1.40
Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A (2005) 1.40
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A (2002) 1.38
Matrix metalloproteinase control of capillary morphogenesis. Crit Rev Eukaryot Gene Expr (2008) 1.32
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res (2002) 1.32
Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials (2007) 1.31
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A (2004) 1.31
Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A (2009) 1.28
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res (2010) 1.28
Mig-6, signal transduction, stress response and cancer. Cell Cycle (2007) 1.28
Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell (2007) 1.28
Adhesion of mesenchymal stem cells to polymer scaffolds occurs via distinct ECM ligands and controls their osteogenic differentiation. J Biomed Mater Res A (2006) 1.27
Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis (2008) 1.26
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene (2005) 1.25
Vitronectin and collagen I differentially regulate osteogenesis in mesenchymal stem cells. Biochem Biophys Res Commun (2006) 1.24
The regulation of osteogenesis by ECM rigidity in MC3T3-E1 cells requires MAPK activation. J Cell Physiol (2007) 1.20
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A (2011) 1.20
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A (2005) 1.16
RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res (2004) 1.15
Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. Angiogenesis (2010) 1.14
Concentration independent modulation of local micromechanics in a fibrin gel. PLoS One (2011) 1.11
MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol (2013) 1.06
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene (2005) 1.06
The effect of cyclic strain on embryonic stem cell-derived cardiomyocytes. Biomaterials (2007) 1.05
E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model. J Cell Sci (2010) 1.05
Stromal cell identity influences the in vivo functionality of engineered capillary networks formed by co-delivery of endothelial cells and stromal cells. Tissue Eng Part A (2013) 1.05
Effects of extracellular matrix density and mesenchymal stem cells on neovascularization in vivo. Tissue Eng Part A (2010) 1.04
A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med (2008) 1.03
The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem (2006) 1.01
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling. Cancer Res (2011) 1.00
Extracellular matrix remodeling, integrin expression, and downstream signaling pathways influence the osteogenic differentiation of mesenchymal stem cells on poly(lactide-co-glycolide) substrates. Tissue Eng Part A (2009) 1.00
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer (2013) 0.98
Assessing the permeability of engineered capillary networks in a 3D culture. PLoS One (2011) 0.98
Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector. J Virol (2004) 0.97
Bone marrow stromal cells stimulate an angiogenic program that requires endothelial MT1-MMP. J Cell Physiol (2012) 0.96
Effects of tissue stiffness, ultrasound frequency, and pressure on histotripsy-induced cavitation bubble behavior. Phys Med Biol (2015) 0.95
Src, PKCalpha, and PKCdelta are required for alphavbeta3 integrin-mediated metastatic melanoma invasion. Cell Commun Signal (2009) 0.95
Recreating the perivascular niche ex vivo using a microfluidic approach. Biotechnol Bioeng (2010) 0.94
A novel three-dimensional model to quantify metastatic melanoma invasion. Mol Cancer Ther (2007) 0.93
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther (2009) 0.91
A mouse model of activating Met mutations. Cell Cycle (2005) 0.91
Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proc Natl Acad Sci U S A (2014) 0.91
In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia (2006) 0.90
MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res (2013) 0.90
Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res (2005) 0.89
Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front Oncol (2013) 0.89
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS One (2013) 0.88
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol (2013) 0.88
Variant in promoter region of platelet-derived growth factor receptor-alpha (PDGFRalpha) gene is associated with the severity and allergic status of childhood asthma. Int Arch Allergy Immunol (2006) 0.87
Capillary morphogenesis in PEG-collagen hydrogels. Biomaterials (2013) 0.87
An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med (2006) 0.86
Met decoys: will cancer take the bait? Cancer Cell (2004) 0.86
The influence of ascorbic acid, TGF-beta1, and cell-mediated remodeling on the bulk mechanical properties of 3-D PEG-fibrinogen constructs. Biomaterials (2009) 0.86
Aqueous two-phase printing of cell-containing contractile collagen microgels. Biomaterials (2013) 0.84
Bone marrow-derived mesenchymal stem cells enhance angiogenesis via their α6β1 integrin receptor. Exp Cell Res (2013) 0.84
Developmental biology: an arresting activity. Nature (2002) 0.84
Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell Melanoma Res (2009) 0.84
Novel protein targeted therapy of metastatic melanoma. Curr Pharm Des (2003) 0.83
Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proc Natl Acad Sci U S A (2011) 0.83
Anthrax fusion protein therapy of cancer. Curr Protein Pept Sci (2002) 0.83